Cardiovascular Disease

The PRESC1SE-MI trial found that a 0/1-hour pathway for assessing patients with suspected myocardial infarction was non-inferior to a more conservative 0/3-hour pathway for safety, but did not reduce the time patients spent in the emergency department.

At ESC Congress 2026, Dr Rami Abu Fanne (Hillel Yaffe Medical Center and Hadassah Medical Center, The Hebrew University of Jerusalem) presented an analysis exploring whether baseline vitamin D levels were associated with metabolic response to semaglutide in people with type 2 diabetes. The study included 5,300 adults and found that higher baseline vitamin D levels were associated with greater improvements in glycemic control and BMI after 12 months of treatment, although no association was observed with lipid outcomes. Dr Abu Fanne spoke to touchCARDIO about the findings and the questions they raise for future research.

The European Society of Cardiology (ESC) has published its first dedicated clinical practice guidelines on cardiac rehabilitation, calling for rehabilitation to be considered a core component of care across a broader range of cardiovascular conditions. Published in the European Heart ...

Prof. Maria Bäck discusses the first dedicated ESC Guidelines on cardiac rehabilitation, why personalization and multidisciplinary care are central to their recommendations, and the importance of increasing referral to rehabilitation programs.

Professor Arnoud van ’t Hof discusses the CELEBRATE trial, the potential benefits of administering antiplatelet therapy before patients with STEMI reach the catheterization laboratory, and what would be needed to translate this approach into clinical practice.

Large language models, wearables and mobile health technologies are increasingly being explored across cardiovascular research and clinical care. At ESC Congress 2026, Dr Jazmin Aguado-Sierra discussed where these tools could add value, and where questions around reliability remain.

AMUNDSEN showed that immediate initiation of evolocumab after myocardial infarction substantially increased LDL-C goal achievement, but did not significantly reduce death or cardiovascular hospitalization at 1 year. Starting evolocumab immediately after myocardial infarction (MI) more than doubled the proportion of patients ...

Phase III SHASTA-3 and SHASTA-4 results showed substantial and sustained triglyceride reductions with plozasiran, alongside fewer acute pancreatitis events.

Phase III ACACIA-HCM results show significant improvements in symptoms and functional capacity with aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.